

Published by
Ministry of Health, Labour and Welfare



Translated by
Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Eletriptan hydrobromide

Zolmitriptan

Naratriptan hydrochloride

Rizatriptan benzoate

June 4, 2019

Therapeutic category

Vasoconstrictors

Non-proprietary name

Eletriptan hydrobromide, zolmitriptan, naratriptan hydrochloride, rizatriptan benzoate

Safety measure

Precautions should be revised in the package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Package Inserts of Prescription Drugs, PAB Notification No. 606 by the Director General of Pharmaceutical Affairs Bureau, MHW, dated April 25, 1997 (Old instructions): Revised language is underlined.

Current	Revision
<p>Important Precautions (N/A)</p>	<p>Important Precautions <u>Triptans including this drug may lead to an exacerbation of headache. If headache does not improve, consider a possibility of “medication overuse headache” and appropriate measures such as discontinuation of administration should be taken.</u></p>
<p>Adverse Reactions Clinically Significant Adverse Reactions (N/A)</p>	<p>Adverse reactions Clinically significant Adverse Reactions <u>Medication overuse headache:</u> <u>Medication overuse headache may occur. If any abnormalities are observed, appropriate measures such as discontinuation of administration should be taken.</u></p>

(Reference) International Headache Society:Cephalalgia 2018;38(1):1-211

N/A: Not Applicable, because the section is not included in the current package insert.

* This drug is designated as a drug requiring preparation of a Drug Guide for Patients.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp